Non-GAAP Financial Measures In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted net income, adjusted earnings per diluted share, adjusted gross profit, adjusted gross margin, free cash flow and adjusted free cash flow conversion. Organic revenues consist of total revenues excluding the effects of currency exchange rates, revenues from current-period acquisitions and pro ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 000-26224 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 51-0317849 (STATE OR O ...

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Q2 2023 Earnings Conference Call July 27, 2023 8:30 AM ET Company Participants Chris Ward - Senior Director, Investor Relations Jan De Witte - President and Chief Executive Officer Lea Knight - Executive Vice President & Chief Financial Officer Conference Call Participants Steven Lichtman - Oppenheimer Rohan Patel - JP Morgan Young Li - Jefferies David Turkaly - JMP Securities Vik Chopra - Wells Fargo Samuel Brodovsky - Truist Securities Ryan Zimmerman ...

For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO. 000-26224 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 51-0317849 (STATE OR ...

Q1 2023 EARNINGS PRESENTATION APRIL 26, 2023 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this presentation. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like "will," "believe," "may," "could," "would," ...

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Q1 2023 Earnings Conference Call April 26, 2023 8:30 AM ET Company Participants Chris Ward – Senior Director-Investor Relations Jan De Witte – President and Chief Executive Officer Mathieu Aussermeier – Vice President-FP&A, Investor Relations and Treasurer Conference Call Participants Vik Chopra – Wells Fargo Ryan Zimmerman – BTIG Craig Bijou – Bank of America Eric Fleming – Raymond James Rohan Patel – JPMorgan Chase Drew Ranieri – Morgan Stanley Opera ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 000-26224 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 51-0317849 (STATE OR OTHER ...

Neurosurgery market recovery offset by CereLink recall and supply challenges Revenues Q4'22 Q4'21 Growth 1 Q4'21 reported revenue includes TWC 2Q4'22 excludes $0.5M of acquired SIA revenues and ($1.1M) in foreign exchange; 3Percentages based on organic revenue, Commentary represents organic performance, Comparisons are to prior year Adj. Gross Profit Adj. EBITDA Adj. EPS Adj. Gross Profit Adj. EBITDA Adj. EPS 0 0.2 0.4 0.6 0.8 1 1.2 $1,043.5 $1,046.4 -20 -15 -10 -5 0 5 10 15 20 FY'21 FY'22 325 335 345 355 3 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 0-26224 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 51-0317849 (STATE O ...

Integra LifeSciences Holdings Corporation. (NASDAQ:IART) Q3 2022 Earnings Conference Call October 26, 2022 8:30 AM ET Company Participants Chris Ward - Senior Director, Investor Relations Jan De Witte - President & Chief Executive Officer Carrie Anderson - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG David Turkaly - JPM Vik Chopra - Wells Fargo Matthew Taylor - Jefferies Steve Lichtman - Oppenheimer Drew Ranieri - Morgan Stanley Richard Newitter - Truist Operator Hello and welc ...